Blab News
Seattle Startup Vedana Therapeutics Raises $46 Million to Develop Dual-Target Migraine Antibodies
On Wednesday, Vedana Therapeutics, a Seattle‑based biotech that has been operating in stealth, announced it has closed a $46 million Series A round and will begin commercializing a portfolio of antibody‑based migraine therapies. The capital will accelerate the company’s dual‑target approach, which blocks two key migraine‑related signaling molecules: calcitonin gene‑related peptide (CGRP) and pituitary adenylate cyclase‑activating polypeptide (PACAP). Vedana also highlighted plans to deliver its treatments via self‑administered, at‑home injections.
Migraine claims roughly 14 % of the global population, or about 1.16 billion people, and ranks as the third most disabling neurological disorder. Current preventive options include non‑specific drugs, triptans for acute relief, and a growing class of biologics that block CGRP. Although CGRP inhibitors have improved outcomes for many, about two‑thirds of sufferers still experience breakthrough attacks. The discovery of PACAP as an additional trigger has spurred research into dual‑target therapies that could address the complex biology of migraine.
Vedana’s strategy is to combine a highly optimized PACAP‑blocking antibody with a dual‑action antibody that simultaneously inhibits both PACAP and CGRP. The company argues that layering the two approaches could provide a comprehensive shield against the variable triggers that produce migraine attacks. Dr. Ernesto Aycardi, Vedana’s chief medical officer, previously led the clinical development of the CGRP antibody AJOVY at Teva and emphasizes that migraine pathology arises from a network of overlapping biochemical signals rather than a single protein.
The leadership team is steeped in migraine drug development. CEO and co‑founder Anurag Agarwal, formerly an investor at Osage University Partners, helped translate academic discoveries into marketable therapies. Chief scientific officer Leon Garcia led the discovery of CGRP and PACAP antibodies at Alder Biopharmaceuticals, which Lundbeck acquired for $1.95 billion. The board is chaired by Dr. Rob Lenz, former head of global development at Amgen and a key figure in the development of the CGRP antibody Aimovig. The convergence of these experts provides a rare blend of commercial and scientific experience.
The Series A round was co‑led by Westlake BioPartners and Canaan Partners, with additional participation from Dawn Biopharma and Alexandria Venture Investments. The $46 million will fund preclinical work, the initiation of phase I safety studies, and preparation for phase II efficacy trials. Vedana acknowledged that it will face competition from large pharmaceutical companies such as Amgen, Eli Lilly, Teva, and Lundbeck, as well as from smaller biotech firms including Mentari Therapeutics and Slate Medicines. The company said that the competitive landscape underscores the urgency of delivering new preventive options.
Vedana stated that while it will employ advanced computational tools and artificial intelligence to accelerate discovery and manufacturing, its core philosophy is to build on the natural evolution of antibodies. The company says natural antibodies have been refined over billions of years of biological selection and that leveraging these structures can enhance safety and efficacy. The at‑home injection format is intended to give patients greater control over their treatment schedule and reduce the need for clinical visits.
At present, Vedana’s lead candidates are in the preclinical stage, and the company has not yet announced specific trial timelines. It plans to begin phase I studies once the preclinical data package is complete and will continue to engage with regulatory authorities and patient groups to ensure its development pathway aligns with clinical needs.
The launch of Vedana Therapeutics signals a new chapter in migraine research, bringing together a deep understanding of migraine biology, a dual‑target therapeutic strategy, and a team with a proven track record in biologics development. If the company’s candidates prove safe and effective, they could offer a preventive option that addresses the unmet needs of the two‑thirds of patients who remain dissatisfied with current CGRP‑only therapies. The company’s progress will be closely watched by patients, clinicians, and investors as it moves toward clinical testing.
Migraine claims roughly 14 % of the global population, or about 1.16 billion people, and ranks as the third most disabling neurological disorder. Current preventive options include non‑specific drugs, triptans for acute relief, and a growing class of biologics that block CGRP. Although CGRP inhibitors have improved outcomes for many, about two‑thirds of sufferers still experience breakthrough attacks. The discovery of PACAP as an additional trigger has spurred research into dual‑target therapies that could address the complex biology of migraine.
Vedana’s strategy is to combine a highly optimized PACAP‑blocking antibody with a dual‑action antibody that simultaneously inhibits both PACAP and CGRP. The company argues that layering the two approaches could provide a comprehensive shield against the variable triggers that produce migraine attacks. Dr. Ernesto Aycardi, Vedana’s chief medical officer, previously led the clinical development of the CGRP antibody AJOVY at Teva and emphasizes that migraine pathology arises from a network of overlapping biochemical signals rather than a single protein.
The leadership team is steeped in migraine drug development. CEO and co‑founder Anurag Agarwal, formerly an investor at Osage University Partners, helped translate academic discoveries into marketable therapies. Chief scientific officer Leon Garcia led the discovery of CGRP and PACAP antibodies at Alder Biopharmaceuticals, which Lundbeck acquired for $1.95 billion. The board is chaired by Dr. Rob Lenz, former head of global development at Amgen and a key figure in the development of the CGRP antibody Aimovig. The convergence of these experts provides a rare blend of commercial and scientific experience.
The Series A round was co‑led by Westlake BioPartners and Canaan Partners, with additional participation from Dawn Biopharma and Alexandria Venture Investments. The $46 million will fund preclinical work, the initiation of phase I safety studies, and preparation for phase II efficacy trials. Vedana acknowledged that it will face competition from large pharmaceutical companies such as Amgen, Eli Lilly, Teva, and Lundbeck, as well as from smaller biotech firms including Mentari Therapeutics and Slate Medicines. The company said that the competitive landscape underscores the urgency of delivering new preventive options.
Vedana stated that while it will employ advanced computational tools and artificial intelligence to accelerate discovery and manufacturing, its core philosophy is to build on the natural evolution of antibodies. The company says natural antibodies have been refined over billions of years of biological selection and that leveraging these structures can enhance safety and efficacy. The at‑home injection format is intended to give patients greater control over their treatment schedule and reduce the need for clinical visits.
At present, Vedana’s lead candidates are in the preclinical stage, and the company has not yet announced specific trial timelines. It plans to begin phase I studies once the preclinical data package is complete and will continue to engage with regulatory authorities and patient groups to ensure its development pathway aligns with clinical needs.
The launch of Vedana Therapeutics signals a new chapter in migraine research, bringing together a deep understanding of migraine biology, a dual‑target therapeutic strategy, and a team with a proven track record in biologics development. If the company’s candidates prove safe and effective, they could offer a preventive option that addresses the unmet needs of the two‑thirds of patients who remain dissatisfied with current CGRP‑only therapies. The company’s progress will be closely watched by patients, clinicians, and investors as it moves toward clinical testing.
